VectorY is an integrated gene therapy company focused on development of therapeutics for CNS, somatic disorders and muscle diseases.
VectorY has raised $138.0M in total funding. The most recent round was Series A. The last funding was announced in November 2023.
VectorY's investors include Insight Partners, EQT Life Sciences, BioGeneration Ventures, MRL Ventures Fund, Benhamou Global Ventures.
VectorY is headquartered in Amsterdam, The Netherlands.
VectorY is an integrated gene therapy company focused on development of therapeutics for CNS, somatic disorders and muscle diseases.
VectorY is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"VectorY — Funding & Investors." VCBacked, November 13, 2023, https://www.vcbacked.co/company/vectory. Accessed August 1, 2026.
VCBacked. (2023). VectorY — Funding & Investors. Retrieved August 1, 2026, from https://www.vcbacked.co/company/vectory
{{cite web |title=VectorY — Funding & Investors |url=https://www.vcbacked.co/company/vectory |website=VCBacked |access-date=August 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated